CDC-RFA-CK21-2102: Strengthening Rocky Mountain spotted fever (RMSF) prevention and control in Arizona tribal lands
Closed
This grant is closed. A newer notice from the same program is forecast: Strengthening Public Health Systems and Services in Indian Country (CDC-RFA-TO-23-00010101SUPP27). Status: Expected deadline April 2, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2021.
Centers for Disease Control - NCEZID offered grants of up to $350,000 (at least $10,000) to tribes. It expected to make about 6 awards worth $1.8 million in total. Applications closed on May 31, 2021.
From the official notice on Grants.gov, last changed April 27, 2021. Checked November 7, 2026.
- Award ceiling$350,000
- Award floor$10,000
- Total funding$1.8 million
- Expected awards6
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 8, 2021 |
|---|---|
| Deadline | May 31, 2021 |
| Archived by Grants.gov | April 30, 2022 |
Who can apply
This opportunity was open to tribes.
- Native American tribal governments (Federally recognized)
This NOFO targets the development of RMSF prevention programs in areas in which brown dog tick transmitted RMSF has been observed. To date, this disease pattern has only been reported in six of tribal communities in Arizona and parts of northern Mexico. Only the six tribal communities in Arizona with reported cases of RMSF during 2015-2020 will be eligible to apply for this cooperative agreement; this includes the White Mountain Apache Tribe (WMAT), San Carlos Apache Tribe (SCAT), Gila River Indian Community (GRIC), Navajo Nation (NN), Hopi Tribe and Tohono O'odham Nation (TON).
Is this a realistic fit?
- Past Tribal Public Health Capacity Building and Quality Improvement Umbrella Cooperative Agreement awards averaged $845,086; this notice allows up to $350,000 per award.
- Most of the program's money (67% over five years) went to tribes.
- No cost sharing or match is required.
What the grant funds
Rocky Mountain spotted fever (RMSF) occurs in epidemic proportions in parts of Arizona tribal lands. Annual incidence of RMSF in certain tribal communities is more the 150 times higher than the national average, and more than 50% of RMSF cases occur in children. Prevention of RMSF require collaboration of human, animal, and environmental health partners. The purpose of this NOFO is to provide resources to American Indian tribal nations impacted by Rocky Mountain spotted fever in Arizona. These resources will support the development and maintenance of RMSF prevention and control programs within their communities by increasing use of evidence-based interventions, developing improved communications products, strengthening RMSF support services like animal control and vector control services within the community, enhancing tracking of key progress indicators, and by providing support to evaluate the use of current RMSF prevention programs. Through this FOA, CDC seeks to fund eligible federally recognized tribes to provide capacity building in strengthening tribal health systems, and evaluate and monitor awarded tribal public health capacity building projects in AI/AN communities. Activities include: Implementation and adaptation of evidence-based interventions to reduce RMSF Development, dissemination, and evaluation of locally-minded communications plan for RMSF Implementation of RMSF program evaluation Development of strengthened RMSF support services (such as animal control, vector control or environmental management) in tribal communities (by training, equipping tribal program or utilizing contracted services)
Who has won Tribal Public Health Capacity Building and Quality Improvement Umbrella Cooperative Agreement grants before
From fiscal 2021 to 2025, Tribal Public Health Capacity Building and Quality Improvement Umbrella Cooperative Agreement (93.772) awarded $93.0 million across 110 grant awards, an average of $845,086 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Southern Plains Tribal Health Board Foundation | Oklahoma | 2 | $6.8 million |
| Chickasaw Nation | Oklahoma | 2 | $6.7 million |
| Wabanaki Public Health & Wellness NPC | Maine | 2 | $6.5 million |
| Northwest Portland Area Indian Health Board | Oregon | 2 | $6.0 million |
| Alaska Native Tribal Health Consortium | Alaska | 2 | $5.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-TO-23-00010101SUPP27, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK21-2102 still open?
No. It closed on May 31, 2021. A newer notice is forecast: CDC-RFA-TO-23-00010101SUPP27, expected deadline April 2, 2027.
Who can apply for Strengthening Rocky Mountain spotted fever (RMSF) prevention and control in Arizona tribal lands?
Centers for Disease Control - NCEZID accepted applications from tribes. The notice adds further conditions, so read its eligibility section.
What is the deadline for Strengthening Rocky Mountain spotted fever (RMSF) prevention and control in Arizona tribal lands?
Closed May 31, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $350,000 each. About $1.8 million in total across about 6 awards.
Who has won Tribal Public Health Capacity Building and Quality Improvement Umbrella Cooperative Agreement grants before?
The largest recipients over five fiscal years were Southern Plains Tribal Health Board Foundation, Chickasaw Nation, Wabanaki Public Health & Wellness NPC. The program made 110 awards worth $93.0 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)